An observational study in Hepatic Sarcoma, sponsored by University Hospital, Strasbourg, France. Completed at 1 site in France. Open to participants aged 1 Year to 25 Years. Per ClinicalTrials.gov, last updated 2023-12-08.
Sponsored by University Hospital, Strasbourg, France · Observational
Undifferentiated embryonal sarcoma of the liver is the 3rd most common malignant liver tumor after hepatoblastoma and hepatocellular carcinoma with a peak incidence between 6 and 10 years of age. Historically, it is a tumor treated only by surgery with a poor prognosis. In the last decade, the combination of more intensive chemotherapy and, more randomly, radiotherapy, has significantly improved the survival rate of these patients. Due to its low incidence, there are few series reported in the literature and to date there is no specific treatment protocol for the management of these tumors.
It seems appropriate to review the management of these tumors in France in order to discuss the best therapeutic strategy.
1,667 studies on the registry are indexed under Sarcoma; 393 are open to participants now.
This study's enrollment of 30 is below the median of 121 across 238 observational studies indexed under Sarcoma.
Browse Sarcoma studies →University Hospital, Strasbourg, France is the lead sponsor of 966 studies on the registry; 342 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patient aged 0 to 25 with treatment carried out in France from 01/01/2008 to 31/12/2018
Exclusion criteria:
Describe the relapse profile of children with undifferentiated hepatic sarcoma according to the therapies received
the primary endpoint is event-free survival (progression, death, relapse) at 3 years.
Time frame: 3 years after treatment
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France